Carbon[2]

Updated: 2026-11-13

Overview

Carboplatin is a second-generation platinum-containing antineoplastic agent developed to reduce the side effects of cisplatin while maintaining therapeutic efficacy. It is classified as an alkylating agent, forming DNA cross-links that inhibit replication in rapidly dividing cancer cells. Approved by the FDA in 1989, carboplatin is listed on the WHO Model List of Essential Medicines. Its milder nephrotoxicity profile makes it preferable for patients with compromised kidney function, though myelosuppression remains a significant dose-limiting factor.

Physical and Chemical Properties

Carboplatin is a diam(m)ineplatinum(II) complex with a cyclobutane-1,1-dicarboxylate ligand, contributing to its improved hydrolytic stability over cisplatin. The powder is hygroscopic and light-sensitive, requiring inert atmosphere packaging for long-term storage. Its aqueous solutions are stable at pH 5–7 but degrade in acidic or alkaline conditions. Unlike cisplatin, carboplatin does not require saline infusion vehicles, simplifying clinical administration protocols.

Main Applications

As a cornerstone of combination chemotherapy regimens, carboplatin is primarily used for ovarian carcinoma (with paclitaxel), small-cell lung cancer, and pediatric tumors. It demonstrates particular efficacy against germ cell tumors when combined with etoposide. Off-label applications include adjuvant therapy for triple-negative breast cancer and palliative treatment for mesothelioma. The drug's predictable pharmacokinetics allow dosing based on glomerular filtration rate (Calvert formula), reducing interpatient variability.

Safety and Storage

Carboplatin carries a GHS06 toxicity classification with mandatory hazard communication in workplace settings. Myelosuppression (thrombocytopenia in particular) requires regular hematologic monitoring during treatment cycles. API storage demands double-sealed containers under nitrogen blanket at 2–8°C, with desiccant packs to prevent hydration. Reconstituted solutions maintain stability for 24 hours at room temperature or 7 days under refrigeration, though bacterial contamination risks necessitate strict aseptic handling.

B2B Procurement Guide

When sourcing carboplatin API, verify the supplier's EDQM Certificate of Suitability (CEP) or FDA Drug Master File compliance. Batch analysis should confirm <0.1% cisplatin impurity and ≥98.5% purity by HPLC. For injectable formulations, pre-qualify manufacturers with EU GMP or PIC/S certifications. Bulk pricing often follows platinum market fluctuations—currently averaging $120/g for GMP material. Consider freeze-dried formulations for tropical climate distribution chains to enhance thermal stability.